# Leaflyze Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/leaflyze-co

- Industry: Software
- Headquarters: Seoul, South Korea
- Website: www.leaflyze.com/
- Latest round: Seed (Nov 4, 2024)
- Investors on record: 2

## About

Based in Seoul, South Korea, and founded in 2024, Leaflyze Co., Ltd. offers a platform that streamlines pharmaceutical guidelines and compliance practices. The company completed its first deal as of November 4, 2024.  Leaflyze is engaged in providing artificial intelligence-driven solutions tailored to the pharmaceutical industry. The company's primary offerings include a comprehensive platform designed to streamline pharmaceutical guidelines and enhance compliance practices, specifically addressing regulatory adherence and information accessibility challenges faced by pharmaceutical professionals. The solutions are developed with the end-user in mind, targeting healthcare providers, regulatory bodies, and pharmaceutical companies requiring up-to-date and accurate information to navigate complex regulatory environments. Leaflyze's products are marketed primarily in North America and Europe, catering to a diverse clientele that includes pharmaceutical manufacturers, healthcare institutions, and regulatory agencies. Leaflyze operates on a revenue model that includes subscription-based services and partnerships with pharmaceutical entities. Clients typically engage in annual contracts to access the company's AI-driven platform, which provides ongoing updates and support to ensure compliance with evolving pharmaceutical regulations. The transaction structure involves direct sales to businesses, enabling them to integrate Leaflyze's technology into their operational frameworks. The flagship product within this portfolio is the AllPharmaGuide, which serves as a vital resource for professionals seeking guidance on pharmaceutical regulations. Pricing plans for these services are structured to cater to varying client needs, allowing organizations to select tiers based on their size and specific requirements.  In November 2024, Leaflyze raised an undisclosed amount of Seed funding led by Bass Venture with participation from Bluepoint Partners. The company plans to utilize this funding to enhance its product offerings, including the development of new features for the AllPharmaGuide platform, which is expected to launch in early 2025. Additionally, Leaflyze aims to expand its market reach into the Asia-Pacific region by the end of 2025, targeting pharmaceutical companies and healthcare providers in countries like Japan and Australia.

## Funding rounds

- Seed, Nov 4, 2024 — Bluepoint Partners, Bass Ventures

## Investors

- Bluepoint Partners (https://capitalatlas.ai/funds/bluepoint-partners) — Seed
- Bass Ventures (https://capitalatlas.ai/funds/bass-ventures) — Seed